GlassScriptPhysician profile
Jeffrey B Hiltz
NPI 1568437572
$177,270.89
in general payments reported to CMS, 2019-2025
47 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $26K · 2021: $26K · 2022: $27K · 2023: $19K · 2024: $28K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Travel and Lodging: $611 · Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,006.25 |
| Travel and Lodging | $611.04 |
| Food and Beverage | $350.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $147,658.79 | 2019-2025 | |
| Shire North American Group INC | $23,100.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,045.93 | 2019-2022 | |
| Lilly USA, LLC | $872.10 | 2019-2022 | |
| Abbvie INC. | $580.03 | 2021-2022 | |
| Astellas Pharma US INC | $558.75 | 2019-2022 | |
| Novo Nordisk INC | $382.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $336.06 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $329.49 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $255.98 | 2019-2021 | |
| Pfizer INC. | $224.36 | 2019-2022 | |
| Amgen INC. | $200.57 | 2019-2022 | |
| Allergan, INC. | $191.60 | 2019-2020 | |
| Amarin Pharma, INC. | $163.07 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $140.62 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hiltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.